2 results
Approved WMOCompleted
The primary objective is, in patients at low-density lipoprotein cholesterol (LDL-C) goal while on statin therapy, with established cardiovascular disease (CVD) or at high risk for CVD, and hypertriglyceridemia (fasting triglycerides [TG] *200 mg/dL…
Approved WMORecruiting
Primary objectives1A. To evaluate the effect of maximal LDL-C reduction by Evolocumab on top of high intensity lipid-lowering therapy , initiated immediately after invasive ACS treatment on functional impairment of non-infarct related artery (non-…